Welcome to our dedicated page for Bioxytran news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran stock.
Bioxytran Inc is a clinical-stage biopharmaceutical company developing oxygen transport and antiviral therapeutics using proprietary carbohydrate-based technologies. The company's research focuses on two primary platforms: hemoglobin-based oxygen carriers for treating tissue hypoxia, and broad-spectrum antiviral drugs that target galectin proteins involved in viral infection and inflammation.
The oxygen transport platform utilizes hemoglobin stabilized with glyco-polymer technology to create molecules significantly smaller than red blood cells, enabling penetration into ischemic tissues beyond blood clots. Target applications include ischemic stroke, traumatic brain injury, chronic kidney disease, and other conditions where oxygen delivery is compromised. The company has established partnerships to develop Universal Oxygen Carriers as potential alternatives to traditional blood transfusions, addressing global blood supply challenges.
The antiviral program employs glycovirology principles to develop therapeutics that antagonize galectins, preventing viral adhesion to host cells. The lead antiviral candidate uses complex carbohydrate structures to target conserved regions on viral spike proteins, providing potential activity against multiple respiratory viruses. Clinical development has progressed under FDA Investigational New Drug applications, with trials evaluating viral clearance rates and safety profiles.
Bioxytran's research approach combines artificial intelligence analysis of biological targets with rational drug design to create optimized carbohydrate-based molecules. The company maintains patent protection for its co-polymer technologies and continues to advance multiple drug candidates through preclinical and clinical development stages. Strategic collaborations with government agencies and industry partners support the company's development programs and manufacturing capabilities.
News and developments related to Bioxytran typically involve clinical trial progress, regulatory clearances, partnership announcements, financing activities, and research findings related to the company's oxygen transport and antiviral platforms. Investors and stakeholders monitor updates on drug candidate advancement, intellectual property developments, and strategic initiatives that may impact the company's path toward potential product commercialization.
BIOXYTRAN, INC. (BIXT) announced successful animal testing results for its Acellular Oxygen Carrier BXT-25, designed to treat COVID-19 and other viral diseases. The treatment showed non-toxicity and full recovery in Swiss Albino mice, even after a significant blood loss. BXT-25 is significantly smaller than a blood cell, allowing it to reach hypoxic areas of the body, potentially revolutionizing treatment for conditions like strokes and neurodegenerative diseases. The company plans to conduct further toxicity studies and aims to submit an Investigational New Drug Application to the FDA for clinical trials on stroke patients. Initial non-clinical studies indicated no toxicity and effective oxygen delivery, bolstering the drug's therapeutic potential.
BIOXYTRAN, INC. (OTCQB: BIXT) is set to present new findings on its Long COVID research at the Emerging Growth Conference on April 5, 2023, from 10:50am to 11:20am EST. CCO Michael Sheikh will discuss a recent peer-reviewed journal article and engage with attendees. Investors are encouraged to preregister for the event to receive updates and have the opportunity to submit questions. Bioxytran is developing innovative antiviral treatments, focusing on unmet medical needs in virology. The conference serves as a platform for public companies to showcase advancements, attracting a broad audience of investors.
FAQ
What is the current stock price of Bioxytran (BIXT)?
What is the market cap of Bioxytran (BIXT)?
